Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Jan. 18, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in New York on behalf of certain purchasers of shares of Abeona Therapeutics Inc (NASDAQ:ABEO) over alleged Securities Laws Violations by Abeona Therapeutics Inc.
Investors who purchased shares of Abeona Therapeutics Inc (NASDAQ: ABEO) have certain options and for certain investors there are short and strict deadlines running. Deadline: February 14, 2017. NASDAQ:ABEO investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that the science behind Abeona’s proposed gene therapy treatment for Sanfilippo syndrome is unviable, that Steven H. Rouhandeh, Abeona Therapeutics, Inc’s Executive Chairman and Principal Executive Officer, previously worked in a high ranking position for a biotech promoter who was convicted of securities fraud and involved in manipulating biotech stocks, and that as a result, Defendants’ statements about Abeona Therapeutics, Inc’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased Abeona Therapeutics Inc (NASDAQ: ABEO) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
